After a relatively quiet 12 months for mergers and acquisitions in 2017, this year is expected to produce a bumper crop of deals between big pharma and biotech.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS